N/A
Manufactured by ROERIG
35,561 FDA adverse event reports analyzed
Last updated: 2026-04-14
ZIPRASIDONE HYDROCHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by ROERIG. The most commonly reported adverse reactions for ZIPRASIDONE HYDROCHLORIDE include DRUG INEFFECTIVE, WEIGHT INCREASED, DIABETES MELLITUS, TYPE 2 DIABETES MELLITUS, ANXIETY. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ZIPRASIDONE HYDROCHLORIDE.
Out of 15,314 classified reports for ZIPRASIDONE HYDROCHLORIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 35,561 FDA FAERS reports that mention ZIPRASIDONE HYDROCHLORIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, WEIGHT INCREASED, DIABETES MELLITUS, TYPE 2 DIABETES MELLITUS, ANXIETY, INSOMNIA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list ROERIG in connection with ZIPRASIDONE HYDROCHLORIDE. Always verify the specific product and NDC with your pharmacist.